

# Because of you

The Kovalsky-Carr Research Fund provides us a perpetual source of income from which we can innovate and expand our research programs. It provides funds that foster collaboration, too, allowing us to bring together scientists with diverse expertise to uncover and address the mechanisms that drive cancer, as well as the side effects and toxicities of various types of cancer and their treatment options.

Because of you, we are making research inroads that otherwise would not be possible. Here are just a few examples of your philanthropic impact.

#### **BLOOD CANCER**


Endocrinologist Laura Calvi, MD, and Corey Hoffman, PhD, (pictured below), recently discovered a novel sequence of events as blood cells age, which leads to various forms of leukemia. They have also identified an existing drug that

could help eliminate inflammation in the blood system that contributes to the disease process. Their research gives hope that a targeted therapy can someday be developed that reduces the impact of the inflammatory process.

"The Kovalsky-Carr Research Fund has been instrumental to our work," says Calvi. "We've used it to further our research, which could lead to new treatment options and cures for leukemia patients."

During the last seven years, the blood cancer research program has received more than \$11M in grant funding from external sources, due in large part to the investment of generous donors like the Kovalsky-Carr Electric Supply company.





### **PANCREATIC CANCER**

"The Kovalsky-Carr Research Fund supports my lab's search for biomarkers that could be used for early detection of pancreatic cancer," says Stephen Spano Mello, assistant professor in the Department of Biomedical Genetics (pictured below). "The fund supports our work and could ultimately lead to new treatments that halt the tumorigenic process."



Adds Mello, "Many people could benefit from this research, including those who are at a higher risk of getting pancreatic cancer, those with familial pancreatitis, patients with pancreatic lesions, and others with a family

history of breast and ovarian cancer. This fund makes a difference."

### **HISTOLOGY**

Histology—the study of microscopic tissues—is fundamental to basic science and it contributes to the WCI's clinical trial work. The Kovalsky-Carr

Research Fund has provided vital support to WCI's Histology Core group, which uses sophisticated equipment to analyze tissue samples, study cell behavior, and look for abnormalities.

"Because of this fund, we've been able to purchase new equipment and maintain and update what we have now," says Mary Georger, a senior technical assistant within WCI's Histology Core group. "Having the best, most current, and technologically advanced equipment is imperative. It helps our cancer researchers speed up the discovery process."

# Thank you

Your unwavering support underscores your belief in our work—and it helps us push the boundaries of discovery to have far-reaching impact.

Thank you for your generosity and for hosting your annual K-C Cup golf tournament, which has always been a wellspring of camaraderie, community, and support. We are hopeful that this tradition will continue in the years to come.

Thank you—your generosity is directly linked to our research progress.

has a rich, 40-year history of excellence in patient care, research, education, and community outreach across New York State. At Wilmot, we will not settle for care based only on today's treatments. We know that we must lead the way to the next generation of therapies—and, with your help, we can.

The Kovalsky-Carr Research
Fund plays such a critical role
in our work. Your philanthropy
helps fuel our research engine.
It provides essential seed funding
that gets important projects



off the ground, which helps us attract federal research support. Your support also makes it possible for us to purchase state-of-the-art equipment, without which our researchers could not advance their work. We are grateful for your support and commitment to advancing cancer research, especially during these challenging times. On behalf of Wilmot and the entire University community, thank you for making a difference in the research we can pursue. You are helping us change the course of cancer. \*\*

## **JONATHAN FRIEDBERG, MD, MMSC**

Director, Wilmot Cancer Institute

